The monoclonal antibody nirsevimab was at least 70% effective in preventing
hospitalisations in infants with lower respiratory tract infections (LRTI) positive for respiratory�…

After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus
(RSV), estimated neonatal coverage was 84%(1,277 doses/1,524 births) in 2023. That year�…

Summary Background Galicia (Spain) was one of the first regions worldwide to incorporate
nirsevimab for universal respiratory syncytial virus (RSV) prophylaxis in infants into its�…

Background Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, resulting
in 3 million hospitalizations each year worldwide. Nirsevimab is a monoclonal antibody�…

To date, safe and effective strategies to prevent medically attended RSV illness across the
infant population have been limited to passive immunoprophylaxis for those at highest risk�…

A systematic review with a meta-analysis was performed to gather available evidence on the
effectiveness of monoclonal antibody nirsevimab in the prevention of lower respiratory tract�…

Background In Catalonia, infants under 6 months old were eligible to receive nirsevimab, a
novel monoclonal antibody against respiratory syncytial virus (RSV). We aimed to analyse�…

Respiratory syncytial virus (RSV) infection is a frequent cause of hospitalisation in the first
few months of life; however, this risk rapidly decreases with age. Nirsevimab�…

Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden,
particularly in newborns and infants during their first year of life. The quest for an effective�…

Background The morbidity burden of respiratory syncytial virus (RSV) in infants extends
beyond hospitalization. Defining the RSV burden before implementing prophylaxis�…